Organogenesis Inc. said yesterday that its wound-healing cell therapy Apligraf is the 1st of its kind to significantly change the genomic profile of a treated chronic wound. The claim was supported by new research done at the University of Miami and published in the journal Science Translational Medicine.
The team applied Apligraf to a chronic venous leg ulcer and studied the wound’s genomic profile, comparing it to compression therapy, which is a standard method of care. The study showed that using the cell therapy in combination with compression therapy changed the wound’s microenvironment and altered the chronic wound’s genomic profile to a healing wound profile.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!